Literature DB >> 2335479

A prospective study of chronic or recurrent headache in systemic lupus erythematosus.

J Vázquez-Cruz1, H Traboulssi, A Rodriquez-De la Serna, C Geli, C Roig, C Diaz.   

Abstract

This study was conducted to analyze the prevalence and features of chronic or recurrent headache in Systemic Lupus Erythematosus (SLE), and also the relationship of such headache with other manifestations of the disease. A total of 76 patients (69 women and 7 men) with a mean age of 40 years (r: 24-74 years) were included. An overall severity index for SLE was applied. Fifty-two patients (68%) presented headache, 27 (52%) being vascular and 25 (48%) muscle contraction type. Headache in general was more frequent after the onset of SLE (p less than .001). Prevalence of muscle contraction headache in particular was greater following manifestations of SLE. Family history of migraine was recorded in 54% of the patients with vascular headache. This antecedent was more common in patients in whom migraine started before the onset of SLE (p = .05). A greater number of neuropsychiatric symptoms was observed in the patients with vascular headache and family history (p less than .02). Patients with thrombocytopenia presented headache less frequently (p less than .05). Our results showed headache, of both vascular and muscle contraction types, to be frequent in SLE. We note that there is an increased frequency of muscle contraction headache after the onset of SLE, and that there is a migraine-like headache directly related to SLE. Migrainous patients with familial history have a greater probability to suffer neuropsychiatric manifestations. Finally, it is suggested that severity of SLE is not related to presence of headache.

Entities:  

Mesh:

Year:  1990        PMID: 2335479     DOI: 10.1111/j.1526-4610.1990.hed3004232.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  8 in total

1.  Prevalence and classification of headache in patients with systemic lupus erythematosus.

Authors:  Bruno Lessa; Alex Santana; Isabella Lima; José Martônio Almeida; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2006-01-26       Impact factor: 2.980

2.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

3.  Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids.

Authors:  H S Markus; N Hopkinson
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

4.  Neuropsychiatric manifestations of systemic lupus erythematosus: Iranian experience.

Authors:  Afshin Borhani Haghighi; Shahab Ghasem Haza
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

5.  Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features.

Authors:  A M Chancellor; R E Cull; D C Kilpatrick; C P Warlow
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

6.  H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report.

Authors:  Emanuele Tinelli; Simona Pontecorvo; Manuela Morreale; Francesca Caramia; Ada Francia
Journal:  Radiol Case Rep       Date:  2018-11-06

Review 7.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

Review 8.  Immunologic aspects of migraine: A review of literature.

Authors:  Mehrnaz Salahi; Sina Parsa; Delaram Nourmohammadi; Zahra Razmkhah; Omid Salimi; Mohammadreza Rahmani; Saeid Zivary; Monireh Askarzadeh; Mohammad Amin Tapak; Ali Vaezi; Hamidreza Sadeghsalehi; Shirin Yaghoobpoor; Mehran Mottahedi; Setareh Garousi; Niloofar Deravi
Journal:  Front Neurol       Date:  2022-09-28       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.